SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

These three biotechs have kicked off the new year in a very bullish way, but where do things go from here for Novavax (NASDAQ:NVAX), Q Biomed (OTCMKTS:QBIO) and Axsome Therapeutics (NASDAQ: AXSM). 2019 seems to be off to a bullish start for the biotech sector and three companies’ have charts that are worth examining as investors wonder what the markets may hold next. Watch the video below to know more:

https://youtu.be/NJ4M3ntPmQI